Nateglinide · more major-labeled pairs than Leflunomide
SPL labels Nateglinide + Leflunomide as minor; Nateglinide 8 / Leflunomide 20 in that band.
Mechanism on file: Leflunomide blocks the proteins that move nateglinide through your body. This can cause the amount of nateglinide in your blood to increase.
FDA SPL severity: Minor
Nateglinide + Leflunomide · SPL mechanism field
Leflunomide blocks the proteins that move nateglinide through your body. This can cause the amount of nateglinide in your blood to increase.
Minor band excerpt · Nateglinide with Leflunomide
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking leflunomide [see Clinical Pharmacology (12.3) ].
Nateglinide · 1 major-labeled pairs (vs Leflunomide's 0)
- Amiodarone minor
- Clonidine minor
- Fluconazole minor
- Octreotide minor
Leflunomide · 20 SPL pairs (broader portfolio than Nateglinide)
- Alosetron minor
- Atorvastatin minor
- Cimetidine minor
- Ciprofloxacin minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.